誉衡药业（002437）：2025年业绩预增符合预期：一次性收益增厚利润，主业修复叠加政策红利打开增长空间

Investment Rating - The investment rating for the company is "Accumulate" (maintained) with a current price of 3.38 CNY and a target price of 3.64 CNY over a 6-month period [1]. Core Insights - The company is expected to achieve a net profit attributable to shareholders of 350 million to 420 million CNY in 2025, representing a year-on-year growth of 50.37% to 80.44% [5][8]. - The core driver of this growth is attributed to a non-recurring investment income of 132 million CNY from the sale of equity in Guangzhou Yuheng Biotechnology Co., Ltd. [8]. - The company’s main business is showing steady recovery, with a projected net profit excluding non-recurring items of 185 million to 220 million CNY, reflecting a moderate growth of 0.92% to 20.02% [8]. Summary by Sections Market Data - Total share capital is 2,232.03 million shares, with a circulation ratio of 98.46% [2]. - The highest and lowest stock prices over the past 12 months were 4.08 CNY and 2.12 CNY, respectively [2]. Performance Metrics - The company has shown relative returns of -3.81% over 1 month, 2.98% over 3 months, and 17.42% over 12 months compared to the CSI 300 index [4]. - Absolute returns were -3.70% over 1 month, 8.68% over 3 months, and 35.74% over 12 months [4]. Financial Forecast - Revenue projections for 2025-2027 are 2,252.80 million CNY, 2,392.24 million CNY, and 2,637.93 million CNY, with growth rates of -7.70%, 6.19%, and 10.27% respectively [10]. - Net profit forecasts for the same period are 352.59 million CNY, 291.40 million CNY, and 351.19 million CNY, with growth rates of 51.48%, -17.35%, and 20.52% respectively [10]. Investment Thesis - The company is positioned to benefit from a dual-track development in the pharmaceutical industry, supported by local policy incentives, which may catalyze performance growth [8]. - The product matrix covers over 300 drug registration certificates across various therapeutic areas, enhancing market penetration [8]. - The company is expected to maintain stable profitability in the existing market while expanding its pipeline and innovating in traditional Chinese medicine [8].